𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Identification of tumor antigens and T-cell epitopes, and its clinical application

✍ Scribed by Annette Paschen; Stefan Eichmuller; Dirk Schadendorf


Publisher
Springer-Verlag
Year
2004
Tongue
English
Weight
172 KB
Volume
53
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Identification of T cell lymphoma tumor
✍ Joseph Kaplan; Jerel Tilton; Ward D. Peterson Jr. πŸ“‚ Article πŸ“… 1976 πŸ› John Wiley and Sons 🌐 English βš– 301 KB πŸ‘ 2 views

## Abstract All human T lymphoblast cell lines have been derived from subjects with leukemia secondary to thymic lymphoblastic lymphoma, a T cell malignacy, suggesting that such lines represent established cultures of neoplastic T cells. Based on this observation, we prepared rabbit antisera to T c

Frameshift peptide-derived T-cell epitop
✍ Michael Linnebacher; Johannes Gebert; Wolfgang Rudy; Stefan Woerner; Yan P. Yuan πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 French βš– 89 KB

## Microsatellite instability (MSI) caused by defective DNA mismatch repair (MMR) is a hallmark of hereditary nonpolyposis colorectal cancers (HNPCC) but also occurs in about 15% of sporadic tumors. If instability affects microsatellites in coding regions, translational frameshifts lead to truncate

Differential presentation of tumor antig
✍ Gerhard Held; Frank Neumann; Christine Sturm; Lars Kaestner; Nina Dauth; Diederi πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 French βš– 311 KB

## Abstract SSX2 is a member of the family of cancer/testis antigens. The SSX2 derived peptide SSX2~103–111~ has been shown to be presented to cytotoxic T‐lymphocytes (CTL) by Major‐Histocompatibility (MHC) Class‐I complexes after endogenous processing, more precisely by the allele HLA‐A\*0201. The

Identification of known and novel immuno
✍ Carmen Scheibenbogen; Yuansheng Sun; Ulrich Keilholz; Mingxia Song; Stefan Steva πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 French βš– 145 KB

## Abstract In previous studies CD8+ T cells specific for melanocyte antigens have been frequently found in melanoma patients responding to interleukin‐2 (IL‐2)‐based therapies. In our study we analyzed the suitability of using circulating T cells from melanoma patients with clinical response after